钠-葡萄糖协同转运蛋白2抑制剂与主要不良心血管事件风险:多数据库回顾性队列研究
主要终点为主要不良心血管事件(心肌梗死、缺血性卒中或心血管死亡的复合终点)。与DPP-4抑制剂相比,SGLT2抑制剂与MACE风险降低相关(HR 0.76,95%CI 0.69-0.84),心肌梗死、心血管死亡、心力衰竭和全因死亡风险亦降低,缺血性卒中的获益较温和(HR 0.85,95%CI 0.72-1.01)。作者结论认为,在真实世界临床实践背景下,短期使用SGLT2抑制剂与心血管事件风险降低相关。
要点
- 在2型糖尿病患者中,SGLT2抑制剂较DPP-4抑制剂与MACE风险降低相关:HR 0.76(95%CI 0.69-0.84),发生率11.4 vs 16.5/1000人年。
- 心血管死亡风险:SGLT2抑制剂组发生率3.9/1000人年 vs DPP-4抑制剂组7.7/1000人年,HR 0.60(95%CI 0.54-0.67)。
- 心力衰竭风险:SGLT2抑制剂组3.1/1000人年 vs DPP-4抑制剂组7.7/1000人年,HR 0.43(95%CI 0.37-0.51)。
- 全因死亡风险:SGLT2抑制剂组8.7/1000人年 vs DPP-4抑制剂组17.3/1000人年,HR 0.60(95%CI 0.54-0.67)。
- 缺血性卒中获益较温和:SGLT2抑制剂组2.6/1000人年 vs DPP-4抑制剂组3.5/1000人年,HR 0.85(95%CI 0.72-1.01),未达统计学显著。
适用人群与场景
- 纳入209 867例SGLT2抑制剂新使用者,按时间条件倾向评分匹配209 867例DPP-4抑制剂使用者,平均随访0.9年。
研究设计与关键结果
- 多数据库回顾性队列研究,采用流行新使用者设计并随后进行Meta分析,纳入209 867例SGLT2抑制剂新使用者与209 867例DPP-4抑制剂使用者,按时间条件倾向评分匹配,平均随访0.9年。
- 主要终点MACE(心肌梗死、缺血性卒中或心血管死亡的复合终点):SGLT2抑制剂组发生率11.4/1000人年 vs DPP-4抑制剂组16.5/1000人年,HR 0.76(95%CI 0.69-0.84)。
- 心肌梗死:SGLT2抑制剂组5.1/1000人年 vs DPP-4抑制剂组6.4/1000人年,HR 0.82(95%CI 0.70-0.96)。
- 心血管死亡:SGLT2抑制剂组3.9/1000人年 vs DPP-4抑制剂组7.7/1000人年,HR 0.60(95%CI 0.54-0.67);心力衰竭:3.1 vs 7.7/1000人年,HR 0.43(95%CI 0.37-0.51);全因死亡:8.7 vs 17.3/1000人年,HR 0.60(95%CI 0.54-0.67)。
- 缺血性卒中:SGLT2抑制剂组2.6/1000人年 vs DPP-4抑制剂组3.5/1000人年,HR 0.85(95%CI 0.72-1.01)。
- MACE获益在卡格列净(HR 0.79,95%CI 0.66-0.94)、达格列净(HR 0.73,95%CI 0.63-0.85)和恩格列净(HR 0.77,95%CI 0.68-0.87)中相似。
证据类型、等级与局限
- 证据类型:多数据库回顾性队列研究(流行新使用者设计)并随后进行Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在真实世界临床实践背景下,短期使用SGLT2抑制剂与DPP-4抑制剂相比与心血管事件风险降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
- 另有 2 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the risk of cardiovascular events between sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among people with type 2 diabetes in a real world context of clinical practice.
DESIGN: Multi-database retrospective cohort study using a prevalent new user design with subsequent meta-analysis.
SETTING: Canadian Network for Observational Drug Effect Studies (CNODES), with administrative healthcare databases from seven Canadian provinces and the United Kingdom, 2013-18.
POPULATION: 209 867 new users of a SGLT2 inhibitor matched to 209 867 users of a DPP-4 inhibitor on time conditional propensity score and followed for a mean of 0.9 years.
MAIN OUTCOME MEASURES: The primary outcome was major adverse cardiovascular events (MACE, a composite of myocardial infarction, ischaemic stroke, or cardiovascular death). Secondary outcomes were the individual components of MACE, heart failure, and all cause mortality. Cox proportional hazards models were used to estimate site specific adjusted hazards ratios and 95% confidence intervals, comparing use of SGLT2 inhibitors with use of DPP-4 inhibitors in an as treated approach. Site specific results were pooled using random effects meta-analysis.
RESULTS: Compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with decreased risks of MACE (incidence rate per 1000 person years: 11.4 v 16.5; hazard ratio 0.76, 95% confidence interval 0.69 to 0.84), myocardial infarction (5.1 v 6.4; 0.82, 0.70 to 0.96), cardiovascular death (3.9 v 7.7; 0.60, 0.54 to 0.67), heart failure (3.1 v 7.7; 0.43, 0.37 to 0.51), and all cause mortality (8.7 v 17.3; 0.60, 0.54 to 0.67). SGLT2 inhibitors had more modest benefits for ischaemic stroke (2.6 v 3.5; 0.85, 0.72 to 1.01). Similar benefits for MACE were observed with canagliflozin (0.79, 0.66 to 0.94), dapagliflozin (0.73, 0.63 to 0.85), and empagliflozin (0.77, 0.68 to 0.87).
CONCLUSIONS: In this large observational study conducted in a real world clinical practice context, the short term use of SGLT2 inhibitors was associated with a decreased risk of cardiovascular events compared with the use of DPP-4 inhibitors.
TRIAL REGISTRATION: ClinicalTrials.gov NCT03939624.
参考来源
- Filion KB, Lix LM, Yu OH, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020. PMID: 32967856. doi:10.1136/bmj.m3342
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。